Antiviral therapy for hepatitis C: why are so few patients being treated?
- 11 May 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (7) , 1327-1329
- https://doi.org/10.1093/jac/dkq157
Abstract
Despite the long-term morbidity associated with hepatitis C and the availability of effective treatment, fewer than a quarter of infected individuals are treated with antiviral therapy. While this is partly related to inherent limitations of currently available medications and the underlying patient population, numerous health system barriers also exist. Fewer than half of chronic hepatitis C infections are diagnosed, relatively few are referred for treatment, and misperceptions about the disease and its treatment abound amongst patients and physicians alike. This article will discuss patient and physician factors that contribute to the undertreatment of chronic hepatitis C.Keywords
This publication has 19 references indexed in Scilit:
- A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C VirusClinical Gastroenterology and Hepatology, 2010
- Public health impact of antiviral therapy for hepatitis C in the United States†Hepatology, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Market uptake of new antiviral drugs for the treatment of hepatitis CJournal of Hepatology, 2008
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced FibrosisAnnals of Internal Medicine, 2007
- Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2007
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- High Rates of Uninsured Among HCV-Positive IndividualsJournal of Clinical Gastroenterology, 2005
- Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver‐related deathJournal of Viral Hepatitis, 2004
- Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trialsBMJ, 2001